Last updated: February 25, 2026
What is the drug identified by NDC 00378-3750?
NDC 00378-3750 refers to Hydroxyprogesterone Caproate Injection. It is used for prevention of preterm birth in women with a history of spontaneous preterm birth or multiple pregnancies.
Market Landscape Overview
Indications and Usage
Hydroxyprogesterone caproate is primarily indicated for pregnant women at high risk of preterm birth. Key markets include the United States, Europe, and Asia.
Market Size and Demand
- U.S. Preterm Birth Market: Approximately 10-12% of births globally are preterm, with U.S. preterm birth rate at about 10.5% as of 2021.
- Market Value: The U.S. preterm birth management market was valued at approximately $250 million in 2022.
- Growth Drivers: Increasing awareness of preterm birth complications and expanding insurance coverage.
Competitors
- Makena (marketed version of hydroxyprogesterone caproate)
- Off-label progesterone treatments
- Emerging therapies targeting preterm birth
Regulatory Status
- U.S. FDA: Approved under the Orphan Drug Act; Makena was approved in 2011.
- Patent Status: Patent expiration occurred in the last decade; market competitiveness opened to generics.
Price Analysis
Current Price Points
- Brand-name (Makena): Wholesale acquisition cost (WAC) around $1,400 - $1,600 per 4 mL vial.
- Generic versions: Available at approximately $400 - $800 per 4 mL vial.
- Insurance Reimbursement: Varies but generally mirrors the 20-50% markup over WAC.
Pricing Trends
- After patent expiration, generic prices declined approximately 30-50%.
- In 2022, the average wholesale price (AWP) ranged from $700 to $1,200 for branded products.
- Reimbursement rates tend to be lower than WAC, affecting profitability.
Price Projections (2023-2028)
| Year |
Estimated Average Price (per 4 mL vial) |
Key Factors Influencing Price |
| 2023 |
$650 - $900 |
Increased competition from generics |
| 2024 |
$600 - $850 |
Market saturation, COVID-19 recovery |
| 2025 |
$550 - $800 |
Potential new formulations, biosimilar entry |
| 2026 |
$500 - $750 |
Patent exclusivity fully expired, price pressure |
| 2027 |
$450 - $700 |
Market stabilization, insurance adjustments |
| 2028 |
$400 - $650 |
Further generic proliferation |
Potential Price Drivers
- New formulations or delivery methods could command a premium.
- Regulatory changes impacting reimbursement.
- Entry of biosimilars or generics affecting prices.
- Healthcare policy shifts towards more cost-effective treatments.
Market Entry and Price Strategy Insights
Key Considerations
- Price sensitivity among payers and providers.
- Differing reimbursement policies across regions.
- Patent status could influence initial pricing strategies.
Recommendations
- Early adoption of cost-effective generic manufacturing could mitigate pricing pressure.
- Collect pricing and reimbursement data regularly to adjust portfolio strategies.
- Explore partnerships with healthcare providers to secure preferred formulary status.
Risks and Opportunities
| Risks |
Opportunities |
| Patent expiration leading to price erosion |
Increasing global demand for preterm birth management |
| Regulatory changes affecting reimbursement |
Adoption of biosimilars reducing costs |
| Market entry of competing therapies |
Expansion into emerging markets with rising preterm birth rates |
Key Takeaways
- Hydroxyprogesterone caproate injection is a key treatment for preterm birth prevention, with a US market valued at around $250 million.
- The market is consolidating with increased generic availability, driving prices downward.
- Current pricing ranges from $400 to $900 per 4 mL vial, with expectations of further reductions over the next five years.
- Price projections reflect ongoing patent expirations, increased competition, and healthcare policy adjustments.
- Pursuing cost-efficient manufacturing and strategic partnerships could optimize market position.
FAQs
Q1: How does patent expiration impact pricing?
Patent expiration typically leads to increased generic competition, reducing prices by 30-50%.
Q2: Are biosimilars expected for hydroxyprogesterone caproate?
Biosimilar development is unlikely due to the molecule’s synthetic nature, but biosimilar-like versions could emerge.
Q3: What is the primary barrier to market penetration in emerging markets?
Regulatory approval processes and reimbursement infrastructure are limited compared to developed markets.
Q4: How does insurance impact drug pricing?
Insurance reimbursement policies often set payment rates below WAC, influencing profit margins.
Q5: Which factors could sustain higher prices in the future?
Innovation in drug delivery, such as extended-release formulations, and regulatory exclusivities could support higher prices.
References
[1] CDC. (2022). Preterm Birth. Centers for Disease Control and Prevention.
[2] IQVIA. (2022). National Sales Data.
[3] FDA. (2011). Makena Approval Documents.
[4] Statista. (2022). US Preterm Birth Market Value.
[5] GoodRx. (2023). Drug Price Comparison Database.
